Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.
Ontology highlight
ABSTRACT: Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations.
SUBMITTER: Friend R
PROVIDER: S-EPMC5367738 | BioStudies | 2017-01-01
SECONDARY ACCESSION(S): NCT02272803
REPOSITORIES: biostudies
ACCESS DATA